Cipla, in collaboration with the UK government, has expressed its intention to make investments of up to 100 million pounds in its UK subsidiary over the next few years. The investments are expected to facilitate the launch of a range of products in the area of respiratory, oncology and antiretroviral medicines to further Cipla’s higher purpose of universal affordable access.
The company also plans to invest in R&D activities, clinical trials and expand further internationally. The investment underscores the growing importance of UK in the company’s long term strategy.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.
